This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Median survival in patients with polycythemia vera (PV), which is 1.5-3 years in the absence of therapy.

The median survival has been extended to approximately 14 years overall, and to 24 years for patients younger than 60 years of age - this is because the availability of new therapeutic tools.

The relationship of the disease to other myeloproliferative disorders is evidenced by the tendency in some patients to transform after a period to acute leukaemia - in 10 to 20% of patients - or to myelofibrosis - in one third of all patients.

Reference:

Tefferi A, Barbui T.Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019 Jan;94(1):133-143


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.